Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697304 · ClinicalTrials.gov registry record · Phase 2
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
NCT03697304 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 211 participants.
The verdict
NCT03697304, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
Study Summary
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors. How long the participants are in the study depends on whether they benefit from treatment and whether they experience unacceptable side effects. The participants are put into different groups. Each group receives BI 754091 in combination with another medicine. The doctors check whether the tumors shrink or disappear. The doctors also check the general health of the participants.
Interventions
- DRUG Ezabenlimab
- DRUG BI 836880
- DRUG BI 754111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03697304
The ClinicalTrials.gov registry entry for NCT03697304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ezabenlimab is the first listed.
NCT03697304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03697304 about?
NCT03697304 is a clinical study titled "Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours". This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called im...
What is the current status of trial NCT03697304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2019-03-19. Estimated completion is 2024-12-03.
What interventions are being tested in trial NCT03697304?
The interventions under investigation include: Ezabenlimab (DRUG), BI 836880 (DRUG), BI 754111 (DRUG).
Who is sponsoring clinical trial NCT03697304?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.